Turkiye Klinikleri Cardiovascular Sciences

.: REVIEW
Kurkuminin Metabolik Sendrom Bileşenleri Üzerine Etkileri
Effects of Curcumin on Metabolic Syndrome Components
Can ERGÜNa, Murat URHANb
aBeslenme ve Diyetetik Bölümü, Bahçeşehir Üniversitesi Sağlık Bilimleri Fakültesi, İstanbul, TÜRKİYE
bBeslenme ve Diyetetik Bölümü, Ege Üniversitesi Sağlık Bilimleri Fakültesi, İzmir, TÜRKİYE
Turkiye Klinikleri J Cardiovasc Sci. 2019;31(1):52-62
doi: 10.5336/cardiosci.2018-62841
Article Language: TR
Full Text
ÖZET
 Kurkumin, zerdeçal olarak bilinen Curcuma longa isimli bitkinin köklerinden elde edilmektedir. Kurkuminin glikoliz aktivasyonu, hepatik glukoneogenezin inhibisyonu ve lipit metabolizmasının azaltılması yoluyla glukoz homeostazına aracılık etmektedir. Nükleer faktör-kappa B inhibitörü olan kurkumin insülin direncinin hafifletilmesinde yardımcıdır; peroksizom proliferatörü aktive reseptör gamayı aktive ederek hipoglisemik etkiler göstermekte ve böylece kan glukoz seviyelerindeki artışları baskılayabilmektedir. Kurkuminin insülin sekresyonu üzerinde bir etkiye sahip olabileceğini gösteren çalışmalar mevcuttur. Arterlerdeki Ang II Tip-1 reseptörü ekspresyonunu düzenleyerek metabolik sendromun önemli bileşenlerinden biri olan hipertansiyon gelişimini önleyebilmektedir. Kurkuminlerin trigliserid düşürücü etkileri çeşitli deneysel çalışmalarda doğrulanmıştır. Trigliserid sentezini düşüren ve yağ asidi oksidasyonunu artıran lipit metabolizması üzerindeki etkisine ek olarak, kurkuminin bazal metabolik hızı ve bazı sitokinlerin salınımını artırarak vücut ağırlığını da azaltabileceğini gösteren kanıtlar bulunmaktadır. Kurkuminlerin hepatik yağ birikimini azalttığı ve lipojenik faktörleri aşağı regüle ederek steatozu önlediği saptanmıştır. Ayrıca, sistemik inflamasyonun biyobelirteçlerini, hepatosit hasarını ve oksidatif stresi azaltmakta, insülin duyarlılığını ve glisemik kontrolü geliştirmektedir. Kurkumin, hepatik enzimler HMG-CoA redüktaz ve açil CoA kolesterol açiltransferazı baskılayarak hepatik kolesterol ve total kolesterol seviyelerini düşürmektedir. Ek olarak, hepatik yağlı asit sentaz aktivitesini inhibe etmekte ve yağ asitlerinin beta oksidasyonunu artırmaktadır. Kurkuminin metabolik sendromun neden olduğu parametreleri düzelterek ve olumsuz etkilerini ortadan kaldırarak metabolik sendromun tedavisinde umut verici bir ajan olduğu düşünülmektedir.

Anahtar Kelimeler: Kurkumin; metabolik sendrom; diabetes mellitus; hipertansiyon
ABSTRACT
 Curcumin is derived from the roots of the plant Curcuma longa known as turmeric. Curcumin mediates glucose homeostasis through activation of glycosis, inhibition of hepatic gluconeogenesis and reducing lipid metabolism. As a nuclear factor kappa B inhibitor, curcumin helps to alleviate insulin resistance; activates peroxisome proliferator-activated receptor gamma and shows hypoglycemic effects and thus suppresses increases in blood glucose levels. There are studies showing that curcumin may have an effect on insülin secretion. By regulating the expression of the Ang II Type-1 receptor in the arteries, it can prevent the development of hypertension, an important component of the metabolic syndrome. The triglyceride-lowering effects of curcumin were confirmed in various experimental studies. In addition to the effects on the lipid metabolism, there is some evidence that curcumin can reduce body weight by increasing the basal metabolic rate and release of some cytokines. Curcumin was found to reduce hepatic fat accumulation and prevent steatosis by down-regulating lipogenic factors. In addition, it reduces the biomarkers of systemic inflammation, hepatocyte injury and oxidative stress, and improves insulin sensitivity and glycemic control. Curcumin reduces hepatic cholesterol and total cholesterol levels by inhibiting hepatic enzymes HMG-CoA reductase and acyl CoA cholesterol acyltransferase. In addition, it inhibits hepatic fatty acid synthase activity and increases beta oxidation of fatty acids. Curcumin is a promising agent in the treatment of metabolic syndrome by correcting the parameters caused by the metabolic syndrome and eliminating its negative effects.

Keywords: Curcumin; metabolic syndrome; diabetes mellitus; hypertension
REFERENCES:
  1. Akpolat M, Tarladaçalışır Y, Uz YH, Metin M, Kızılay G. [The use of curcumin in cancer treatment]. Yeni Tıp Dergisi. 2010;27:142-7.
  2. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017;57(13):2889-95. [Crossref ] [PubMed]
  3. Jayaprakasha GK, Jagan L, Sakariah KK. Chemistry and biological activities of C. longa. Trends Food Sci Technol. 2005;16(12):533-48. [Cross ref]
  4. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(2):141-53. [PubMed ]
  5. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32(6):1053-64. [Crossref ] [PubMed]
  6. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10. [Crossref ] [PubMed] [PMC]
  7. Balkan F. [Metabolic syndrome]. Ankara Medical Journal. 2013;13(2):85-90.
  8. Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa M, et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull. 2005;28(5):937-9. [Crossref ] [PubMed]
  9. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008; 149(7):3549-58. [Crossref ] [PubMed] [PMC]
  10. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11): 2121-7. [Crossref] [PubMed] [PMC]
  11. Wickenberg J, Ingemansson SL, Hlebowicz J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J. 2010;9:43. [Crossref ] [ PubMed] [PMC]
  12. Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebocontrolled trial. Mol Nutr Food Res. 2013;57(9):1569-77. [Crossref ] [PubMed]
  13. Terra X, Quintero Y, Auguet T, Porras JA, Hernández M, Sabench F, et al. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol. 2011;164(4):539-47. [Crossref] [PubMed]
  14. Na LX, Yan BL, Jiang S, Cui HL, Li Y, Sun CH. Curcuminoids target decreasing serum adipocyte-fatty acid binding protein levels in their glucose-lowering effect in patients with type 2 diabetes. Biomed Environ Sci. 2014;27(11):902-6. [PubMed ]
  15. Saiah E. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors. Curr Med Chem. 2008;15(7):642-9. [Crossref] [PubMed]
  16. Hu GX, Lin H, Lian QQ, Zhou SH, Guo J, Zhou HY, et al. Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats. PLoS One. 2013;8(3):e49976. [Crossref] [PubMed] [PMC]
  17. Onat A, Yazıcı M, Sarı İ, Türkmen S, Uzunlar B, Uyarel H, et al. [The risk factor survey of 2003 in western Turkey indicates trend to declining coronary mortality and urban overall mortality]. Türk Kardiyol Dern Arş. 2003;31: 762-9.
  18. Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system--focusing on the vascular system. Peptides. 2011;32(10):2141-50. [Crossref] [PubMed]
  19. Yao Y, Wang W, Li M, Ren H, Chen C, Wang J, et al. Curcumin exerts its anti-hypertensive effect by down-regulating the AT1 receptor in vascular smooth muscle cells. Sci Rep. 2016;6:25579. [Crossref] [PubMed] [PMC]
  20. Nakmareong S, Kukongviriyapan U, Pakdeechote P, Kukongviriyapan V, Kongyingyoes B, Donpunha W, et al. Tetrahydrocurcumin alleviates hypertension, aortic stiffening and oxidative stress in rats with nitric oxide deficiency. Hypertens Res. 2012;35(4):418-25. [Crossref] [PubMed]
  21. Hsu SJ, Lee JY, Lin TY, Hsieh YH, Huang HC, Lee FY, et al. The beneficial effects of curcumin in cirrhotic rats with portal hypertension. Biosci Rep. 2017;37(6). [Crossref ] [PubMed]
  22. Silva BR, Pernomian L, De Paula TD, Grando MD, Bendhack LM. Endothelial nitric oxide synthase and cyclooxygenase are activated by hydrogen peroxide in renal hypertensive rat aorta. Eur J Pharmacol. 2017;814:87-94. [Crossref] [PubMed ]
  23. Li Y, Tian D, Zhu C, Ren L. Demethoxycurcumin preserves renovascular function by downregulating COX-2 expression in hypertension. Oxid Med Cell Longev. 2016;2016: 9045736. [Crossref] [PubMed] [PMC]
  24. Ferguson JJA, Stojanovski E, MacDonald-Wicks L, Garg ML. Curcumin potentiates cholesterollowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial. Metabolism. 2018;82:22-35. [Crossref] [PubMed]
  25. Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16(1):68. [Crossref ] [PubMed] [PMC]
  26. Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A. Curcumin as a potential candidate for treating hyperlipidemia: a review of cellular and metabolic mechanisms. J Cell Physiol. 2018;233(1):141-52. [Crossref ] [ PubMed]
  27. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol. 2013;113(3):152-7. [Cross - ref] [PubMed]
  28. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol. 2014;11(2):123. [Crossref ] [ PubMed]
  29. Rachmawati H, Soraya IS, Kurniati NF, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm. 2016;84(1): 131-40. [Crossref] [PubMed] [PMC]
  30. Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev. 2010; 68(12):729-38. [Crossref ] [ PubMed]
  31. Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7A-hydroxylase in rats fed a high fat diet. Nutr Res Pract. 2010;4(3):191-5. [Crossref] [PubMed] [PMC]
  32. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr. 2001;131(11):2932-5. [Crossref ] [ PubMed]
  33. Tu Y, Sun D, Zeng X, Yao N, Huang X, Huang D, et al. Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat diet. Exp Ther Med. 2014;8(1):260-6. [Cross - ref] [PubMed] [PMC]
  34. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep. 2006;15(6):1557-62. [PubMed ]
  35. Meydani M, Hasan ST. Dietary polyphenols and obesity. Nutrients. 2010;2(7):737-51. [Crossref ] [PubMed] [PMC]
  36. Yudkin JS, Kumari M, Humphries SE, MohamedAli V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-14. [Crossref ]
  37. Ganjali S, Sahebkar A, Mahdipour E, Jamialahmadi K, Torabi S, Akhlaghi S, et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal. 2014;2014:898361. [Crossref] [PubMed] [PMC]
  38. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr. 2015;34(6): 1101-8. [Crossref] [PubMed]
  39. Bradford PG. Curcumin and obesity. Biofactors. 2013;39(1):78-87. [Crossref ] [ PubMed]
  40. Ding L, Li J, Song B, Xiao X, Zhang B, Qi M, et al. Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol Appl Pharmacol. 2016;304:99-109. [Crossref ] [PubMed]
  41. Taskinen MR, Söderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietiläinen KH, et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J Intern Med. 2017;282(2):187-201. [Crossref ] [PubMed]
  42. Crescenzo R, Cigliano L, Mazzoli A, Cancelliere R, Carotenuto R, Tussellino M, et al. Early effects of a low fat, fructose-rich diet on liver metabolism, insulin signaling, and oxidative stress in young and adult rats. Front Physiol. 2018;9:411. [Cross ref] [PubMed] [PMC]
  43. Schultz A, Barbosa-da-Silva S, Aguila MB, Mandarim-de-Lacerda CA. Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose. Food Funct. 2015;6(5):1684-91. [Crossref] [PubMed]
  44. Maithilikarpagaselvi N, Sridhar MG, Swaminathan RP, Sripradha R, Badhe B. Curcumin inhibits hyperlipidemia and hepatic fat accumulation in high-fructose-fed male wistar rats. Pharm Biol. 2016;54(12):2857-63. [Cross - ref] [PubMed]
  45. Wang S, Wang X, Ye Z, Xu C, Zhang M, Ruan B, et al. Curcumin promotes browning of white adipose tissue in a norepinephrine-dependent way. Biochem Biophys Res Commun. 2015;466(2):247-53. [Crossref ] [PubMed]
  46. Kim SW, Choi JH, Mukherjee R, Hwang KC, Yun JW. Proteomic identification of fat-browning markers in cultured white adipocytes treated with curcumin. Mol Cell Biochem. 2016;415(1-2):51-66. [Crossref ] [PubMed]
  47. Kim CY, Le TT, Chen C, Cheng JX, Kim KH. Curcumin inhibits adipocyte differentiation through modulation of mitotic clonal expansion. J Nutr Biochem. 2011;22(10):910-20. [Crossref] [PubMed]
  48. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804-9. [Crossref ] [ PubMed]
  49. Di Pierro F, Bressan A, Ranaldi D, Rapacioli G, Giacomelli L, Bertuccioli A. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur Rev Med Pharmacol Sci. 2015;19(21):4195-202. [PubMed ]
  50. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M. Curcumin modulation of high fat dietinduced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis. 2014;232(1):40-51. [Crossref ] [PubMed]
  51. Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014;28(12):1770-7. [Crossref ] [PubMed]
  52. Olszanecki R, Jawień J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, et al. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol. 2005;56(4):627-35. [PubMed ]
  53. Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303-12. [Crossref ]
  54. Tarçın Ö. [Paraoxonase-1 and coronary heart diseases]. Marmara Medical Journal. 2011; 24(1):59-63.
  55. Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fatfed hamsters. Metabolism. 2008; 57(11):1576-83. [Crossref] [PubMed]
  56. Zhang S, Zou J, Li P, Zheng X, Feng D. Curcumin protects against atherosclerosis in apolipoprotein E-knockout mice by inhibiting toll-like receptor 4 expression. J Agric Food Chem. 2018;66(2):449-56 [Crossref ] [PubMed]
  57. Wan Q, Liu ZY, Yang YP, Liu SM. Effect of curcumin on inhibiting atherogenesis by down-regulating lipocalin-2 expression in apolipoprotein E knockout mice. Biomed Mater Eng. 2016;27(6):577-87. [Crossref ] [PubMed]
  58. Feng M, Rached F, Kontush A, Chapman MJ. Impact of lipoproteins on atherobiology: emerging insights. Cardiol Clin. 2018;36(2): 193-201. [Crossref] [PubMed]
  59. Tian N, Li X, Luo Y, Han Z, Li Z, Fan C. Curcumin regulates the metabolism of low density lipoproteins by improving the C-to-U RNA editing efficiency of apolipoprotein B in primary rat hepatocytes. Mol Med Rep. 2014;9(1):132-6. [Crossref ] [PubMed]

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com